Prodrugs of NH-acidic compounds
The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
1. A compound of Formula XIH:
or a pharmaceutically acceptable salt thereof;
wherein:
X is —O—;
each G 3 and G 4 is independently selected from the group consisting of —N— and —C(R 10 )—[C(R 10 )(R 11 )] a —, wherein a is 0;
A is selected from the group consisting of absent, alkyl, alkenyl, alkynyl, —S—, —O—, —S(O)—, —S(O) 2 —, —S[C(R 30 )(R 31 )] u —, —S(O)[C(R 30 )(R 31 )] u —, —S(O) 2 [C(R 30 )(R 31 )] u —, —O[C(R 30 )(R 31 )] u —, —N(R 30 )—, —N(R 30 )[C(R 31 )(R 32 )] u —, —[C(R 30 )(R 31 )] u , —C(O)[C(R 30 )(R 31 )] u —;
B is absent, or a linker, wherein the linker is selected from the group consisting of a bond, a straight chain C 1 -C 10 alkyl, C 1 -C 10 alkenyl, C 1 -C 10 alkynyl, C 1 -C 10 alkoxy, alkoxyC 1 -C 10 alkoxy, C 1 -C 10 alkylamino, alkoxyC 1 -C 10 alkylamino, C 1 -C 10 alkylcarbonylamino, C 1 -C 10 alkylaminocarbonyl, aryloxyC 1 -C 10 alkoxy, aryloxyC 1 -C 10 alkylamino, aryloxvC 1 -C 10 alkylamino carbonyl, C 1 -C 10 -alkylaminoalkylaminocarbonyl, C 1 -C 10 alkyl(N-alkyl)aminoalkyl-aminocarbonyl, alkylaminoalkylamino, alkylcarbonylaminoalkylamino, alkyl(N-alkyl)aminoalkylamino, (N-alkyl)alkylcarbonylaminoalkylamino, alkylaminoalkyl, alkylaminoalkylaminoalkyl, alkylpiperazinoalkyl, piperazinoalkyl, alkylpiperazino, alkenylaryloxyC 1 -C 10 alkoxy, alkenylarylaminoC 1 -C 10 alkoxy, alkenylaryllalkylaminoC 1 -C 10 alkoxy, alkenylaryloxyC 1 -C 10 alkylamino, alkenylaryloxyC 1 -C 10 alkylaminocarbonyl, piperazinoalkylaryl, heteroarylC 1 -C 10 alkyl, heteroarylC 2 -C 10 alkenyl, heteroarylC 2 -C 10 alkynyl, heteroarylC 1 -C 10 alkylamino, heteroarylC 1 -C 10 alkoxy, heteroaryloxyC 1 -C 10 alkyl, heteroaryloxyC 2 -C 10 alkenyl, heteroaryloxyC 2 -C 10 alkynyl, heteroaryloxyC 1 -C 10 alkylamino or heteroaryloxyC 1 -C 10 alkoxy;
D is selected from the group consisting of absent, —O—, —NR 33 , —C(R 34 )(R 35 )—, —S—, —S(O)—, —S(O) 2 —, —C(O)—;
R 1 is selected from the group consisting of —C(R A )(R B )—OC(O)OR 20 , —C(R A )(R B )—OC(O)R 20 , and —C(R A )(R B )—OC(O)NR 20 R 21 ;
each R 2 , R 30 , R 31 , R 32 R 33 , R 34 , and R 35 is independently selected from the group consisting of absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, —C(O)R 10 , aliphatic, aryl, or heterocyclyl;
each R A and R B is independently selected from the group consisting of hydrogen, halogen, aliphatic, and aryl;
each R 10 and R 11 is independently hydrogen, halogen, aliphatic, or aryl; alternatively two R 10 and R 11 together with the atoms to which they are attached and any intervening atoms may form an additional 3, 4, 5, 6 or 7 membered ring;
each R 20 and R 21 is independently selected from hydrogen, aliphatic, or aryl;
R 5 is selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, —C(O)R 10 , aliphatic, and heterocyclyl;
or is selected from:
R 100 and R 101 each represent 1 to 4 substituents independently selected from hydrogen, halogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 8 alkoxy, C 1 -C 8 alkylamino and aryl;
R 103 is selected from hydrogen, halogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 8 alkoxy, C 1 -C 8 alkylamino and aryl;
p is 0, 1, 2, or 3; and
u is independently 1, 2, 3, 4, 5, 6 or 7.
2. The compound of claim 1 , wherein R 5 is selected from:
wherein:
R 100 and R 101 , each represent 1 to 4 substituents independently selected from hydrogen, halogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 8 alkoxy, C 1 -C 8 alkylamino, and aryl; and,
R 103 is selected from hydrogen, halogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 8 alkoxy, C 1 -C 8 alkylamino, and aryl.
3. The compound of claim 1 , wherein R 1 is selected from:
4. A compound according to claim 1 wherein R 1 is elected from:
5. The compound of claim 1 , wherein the compound of Formula XIH is a compound of Formula XI-I:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5 , wherein the compound of Formula XI-I is selected from: